...not expect an advisory committee meeting (see “Data Set Up Submissions” ). Cabotegravir non-inferior to Truvada...
...Healthcare Ltd. said long-acting, injectable cabotegravir met the primary endpoint of non-inferiority to SOC Truvada emtricitabine/tenofovir...

...of all four of the CDC's PrEP patents covering HIV drugs Truvada emtricitabine/tenofovir and Descovy emtricitabine/tenofovir...
...invalid. Separately, CDC filed suit in November seeking royalties and damages from Gilead, asserting that Truvada...
...monoamine transporter 2 BioCentury Staff valoctocogene roxaparvovec (bmn 270) Descovy (Brand), emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other) Truvada, emtricitabine/tenofovir elafibranor...

...9 Sandi Wong, Assistant Editor remdesivir, GS-5734 Tamiflu, oseltamivir (GS 4104, Ro 64-0796) Kaletra, lopinavir/ritonavir (ABT-378/r) Avigan, favipiravir (T-705) Descovy (Brand), emtricitabine/tenofovir...

...in documents filed Thursday that CDC’s four patents for HIV drugs Truvada emtricitabine/tenofovir and Descovy emtricitabine/tenofovir...
...in patients while avoiding side effects (see “Schizophrenia Combo Clears Phase II Bar” ). BioCentury Staff Truvada, emtricitabine/tenofovir Tecentriq...

...federal court to pause a patent infringement lawsuit the federal government filed against the company’s Truvada...
...government in the U.S. District Court for the District of Delaware, asserts that in marketing Truvada...
...studies on emtricitabine/tenofovir as PrEP. The government’s suit contends that prior to FDA approval of Truvada...

...was new evidence of added benefit over existing treatments based on long-term data. For Genvoya elvitegravir/cobicistat/emtricitabine/tenofovir...
...data from randomized controlled trials to ICER that showed that Genvoya was superior to Stribild elvitegravir/cobicistat/emtricitabine/tenofovir...
...price increase, $688 million total cost increase) and Cialis tadalafil (33%, $403 million); Gilead’s Truvada emtricitabine/tenofovir...

...follow-on to Truvada for PrEP as Truvada's patent expires in 2021. An authorized generic of Truvada...
...market next September (see "Gilead sees Descovy as Successor to Truvada for HIV PrEP" ). Truvada’s...
...PrEP patients on Truvada. Jonathan Block, Associate Editor Descovy (Brand), emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other) Truvada, emtricitabine/tenofovir Gilead...

...virus postinfection, they are also looking at ways to prevent HIV infection. Antiretroviral drug Truvada emtricitabine/tenofovir...
...is dependent on a patient’s adherence to daily dosing, and is associated with safety issues. Truvada's...

...2015. Gilead said published materials describe the invention as early as 2004. The company's Truvada emtricitabine/tenofovir...
...the infection; two weeks ago FDA’s Antimicrobial Drugs Advisory Committee backed Gilead's HIV therapy Descovy emtricitabine/tenofovir...

...HIV drug Biktarvy Gilead Sciences Inc. (NASDAQ:GILD) said China's National Medical Products Administration approved Biktarvy bictegravir/emtricitabine/tenofovir...
...to for a U.S. launch in 1Q20. Val Kennedy, Associate Editor and Mary Romeo, Assistant Editor Biktarvy, bictegravir/emtricitabine/tenofovir...